PODCAST: 12/22/2022 (December 12, 2022) | By Life Science Success. In this episode of Life Science Success, my guest is Ross Youngs. Ross is the CEO and Founder of Biosortia Pharmaceutical. Ross is working to Provide previously unobtainable drug-like small molecules directly from microbiomes. LinkedIn
Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing (December 21, 2022) BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences today announced that it has closed a $68-million equity and debt financing. Dimension led the Series B round, which included participation by multiple new institutional investors, including FPV, Jazz Venture Partners, Level Ventures, Amino Collective, Allen &
Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates (December 13, 2022) | By Tyler Patchen. Wave Life Sciences has picked up another deal with a major pharma company. The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance
Amgen Is Said to Agree to Buy Horizon at $26 Billion Value (December 12, 2022) | By Katie Roof, Michelle F Davis, and Dinesh Nair. Amgen agrees to pay around $116.5 for each Horizon share Sanofi, Johnson & Johnson both walked away from discussions Amgen Inc. has agreed to buy Horizon Therapeutics Plc at a
Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions (December 07, 2022) | By Paragon Therapeutics. Apogee emerges with $169 million to expand team and progress lead program APG777 into the clinic Milestone validates Paragon’s strategy to rapidly deliver best-in-class biologic therapies to patients WALTHAM, Mass., Dec. 7,
